Abstract:Objectives Lupus nephritis (LN) is a common and severe manifestation of SLE. Memory T (TM) cells have been implicated in the pathogenesis of SLE. This study aimed to investigate the clinical significance of T-cell subsets in a cohort of patients with LN. Method The peripheral blood T cells of 24 patients with LN and 13 patients with idiopathic membranous nephropathy (iMN) were analysed by flow cytometry. SLE disease activity was evaluated by SLE Disease Activity Index-2000 (SLEDAI-2K). Patients with LN were followed up for >6 months. Results Patients with LN presented lower frequency of CDC` cells and higher percentage of CD8(+) cells than patients with iMN, which was primarily due to lower CD4(+ )cell count. Interestingly, patients with LN under immunosuppressants had lower CD8(+)CD45R0 - TM frequency (p=0.007), fewer regulatory CD4(+) T cells (p=0.04) than those without immunosuppressants. Most CD4+ and CD8(+) TM cells in patients with LN showed an effector memory (C045RO(+)CCR7(+)) phenotype. The frequency of CD8(+)CD45R0(+) TM cells among the CD8(+) T cells was negatively correlated with white blood cell count, haemoglobin, platelet and serum levels of complements C3 and C4, but was positively correlated with serum IgG, erythrocyte sedimentation rate and SLEDAI score (p<0.05 each). Consistently, the frequency of CD8(+)CD45R0(+) TM cells was higher in patients with LN with positive antidouble-stranded DNA antibody, active renal disease, extrarenal manifestations and with sderotic glomeruli or moderate-to-severe mesangial hypercellularity in renal pathology (p<0.05). Additionally, CD8(+)CD45R0(+) TM cell frequency was significantly lower in patients with LN with renal complete remission than that in non-remission LN (18.7% vs 31.2%, p<0.05). None of these significant correlations was observed in CD4(+). TM cells. Conclusion The frequency of CD8(+) TM cells correlates with disease activity and treatment response to immunosuppressant in patients with LN. CD8(+) TM monitoring in patients with LN could provide more helpful indices for the monitoring and management of this disease.

Novel Therapies In Lupus Nephritis Associated With Regulatory T Cells

Targeted therapies for lupus nephritis: Current perspectives and future directions

New insights for regulatory T cell in lupus nephritis

The novel involvement of podocyte autophagic activity in the pathogenesis of lupus nephritis.

Progress of the relationship of regulatory T cells and human systemic lupus erythematosus

Individualizing Therapy in Lupus Nephritis.

Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus

Novel Mitophagy Inducer Alleviates Lupus Nephritis by Reducing Myeloid Cell Activation and Autoantigen Presentation.

Transcription Factors in the Pathogenesis of Lupus Nephritis and Their Targeted Therapy

Treatment of lupus nephritis: consensus, evidence and perspectives

Lupus Nephritis from Pathogenesis to New Therapies: An Update

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

TLR4+CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus

Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients

Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration

Progress in traditional Chinese medicine and natural extracts for the treatment of lupus nephritis

New and emerging therapies for systemic lupus erythematosus

TGF-β-Induced CD8+CD103+ Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells.

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis

Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells

Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses